Want to see MNKD full AI Analyst Report?
MNKD Stock Chart & Stats
$2.84
-$0.05(-0.80%)
At close: 4:00 PM EST
$2.84
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)4.84M
Market Cap
$1.25B
Enterprise Value$1.06K
Total Cash (Recent Filing)$133.86M
Total Debt (Recent Filing)$436.67M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 12, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding308,950,160
10 Day Avg. Volume4,296,104
30 Day Avg. Volume4,842,876
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.15Price Target Upside186.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$462.99M
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing DurabilityA sole-manufacturer supply agreement with contractual minimums creates a predictable, recurring revenue floor and strengthens long-term manufacturing utilization. This reduces top-line volatility from partner sales cycles, supports capacity planning, and underpins durable cash generation and margin stability.
Recurring Royalty Cash FlowGrowing, recurring royalties from partner commercialization provide steady, high-margin cash inflows that fund R&D, debt paydown, and inorganic opportunities. Such non-dilutive cash helps sustain operations through development cycles and improves financial flexibility over multiple quarters.
Expanded Afrezza Addressable MarketPediatric approval enlarges Afrezza's addressable population and fulfills a key postmarketing obligation, reducing regulatory overhang. This structural expansion supports longer-term prescription growth, lifecycle extension, and better payer negotiations as pediatric use becomes an enduring revenue contributor.
Bears Say
Negative Shareholders' EquityPersistent negative equity is a structural balance-sheet weakness that limits strategic flexibility. It constrains access to unsecured capital, raises refinancing risk, and can hamper deal-making or large investments, forcing reliance on partner funding or dilutive financing over the medium term.
Earnings VolatilityRecurrent swings between profit and loss undermine free cash flow predictability and complicate multi-year planning. Volatile net income increases reliance on partner milestones and royalties, raises refinancing and budgeting risk, and makes sustained margin improvement harder to underwrite.
Manufacturing Revenue VariabilityOperational scheduling variability at a key facility makes contract manufacturing revenue lumpy and reduces forecast reliability. Unpredictable output can strain partner relationships, depress short-term margins when fixed costs are underutilized, and complicate capacity investments tied to durable revenue growth.
MannKind News
MNKD FAQ
What was MannKind Corporation’s price range in the past 12 months?
MannKind Corporation lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is MannKind Corporation’s market cap?
MannKind Corporation’s market cap is $1.25B.
When is MannKind Corporation’s upcoming earnings report date?
MannKind Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 25 days.
How were MannKind Corporation’s earnings last quarter?
MannKind Corporation released its earnings results on May 06, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.05.
Is MannKind Corporation overvalued?
According to Wall Street analysts MannKind Corporation’s price is currently Undervalued.
Does MannKind Corporation pay dividends?
MannKind Corporation does not currently pay dividends.
What is MannKind Corporation’s EPS estimate?
MannKind Corporation’s EPS estimate is >-0.01.
How many shares outstanding does MannKind Corporation have?
MannKind Corporation has 308,950,160 shares outstanding.
What happened to MannKind Corporation’s price movement after its last earnings report?
MannKind Corporation reported an EPS of -$0.05 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went down -0.281%.
Which hedge fund is a major shareholder of MannKind Corporation?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.15 (186.97% Upside)
$8.15 (186.97% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 853.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.23%
12-Months-Change
Fundamentals
Return on Equity
45.59%
Trailing 12-Months
Asset Growth
81.50%
Trailing 12-Months
Company Description
MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MNKD Stock 12 Month Forecast
Average Price Target
$8.15
▲(186.97% Upside)
Technical Analysis
Ownership Overview
2.61% Insiders
10.14% Mutual Funds
1.62% Other Institutional Investors
69.45% Public Companies and
Individual Investors